190 related articles for article (PubMed ID: 31972992)
41. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
[TBL] [Abstract][Full Text] [Related]
42. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy.
Lehe C; Ghebeh H; Al-Sulaiman A; Al Qudaihi G; Al-Hussein K; Almohareb F; Chaudhri N; Alsharif F; Al-Zahrani H; Tbakhi A; Aljurf M; Dermime S
Cancer Res; 2008 Aug; 68(15):6350-9. PubMed ID: 18676860
[TBL] [Abstract][Full Text] [Related]
43. The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays.
Britten CM; Meyer RG; Kreer T; Drexler I; Wölfel T; Herr W
J Immunol Methods; 2002 Jan; 259(1-2):95-110. PubMed ID: 11730845
[TBL] [Abstract][Full Text] [Related]
44. Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.
Oren R; Hod-Marco M; Haus-Cohen M; Thomas S; Blat D; Duvshani N; Denkberg G; Elbaz Y; Benchetrit F; Eshhar Z; Stauss H; Reiter Y
J Immunol; 2014 Dec; 193(11):5733-43. PubMed ID: 25362181
[TBL] [Abstract][Full Text] [Related]
45. Mixed functional characteristics correlating with TCR-ligand koff -rate of MHC-tetramer reactive T cells within the naive T-cell repertoire.
Hombrink P; Raz Y; Kester MG; de Boer R; Weißbrich B; von dem Borne PA; Busch DH; Schumacher TN; Falkenburg JH; Heemskerk MH
Eur J Immunol; 2013 Nov; 43(11):3038-50. PubMed ID: 23893393
[TBL] [Abstract][Full Text] [Related]
46. Artificial antigen-presenting cells expressing CD80, CD70, and 4-1BB ligand efficiently expand functional T cells specific to tumor-associated antigens.
Zeng W; Su M; Anderson KS; Sasada T
Immunobiology; 2014 Aug; 219(8):583-92. PubMed ID: 24713579
[TBL] [Abstract][Full Text] [Related]
47. A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy.
Cho HI; Kim UH; Shin AR; Won JN; Lee HJ; Sohn HJ; Kim TG
Br J Cancer; 2018 Feb; 118(4):534-545. PubMed ID: 29360818
[TBL] [Abstract][Full Text] [Related]
48. Flow cytometry-based TCR-ligand Koff -rate assay for fast avidity screening of even very small antigen-specific T cell populations ex vivo.
Nauerth M; Stemberger C; Mohr F; Weißbrich B; Schiemann M; Germeroth L; Busch DH
Cytometry A; 2016 Sep; 89(9):816-25. PubMed ID: 27564267
[TBL] [Abstract][Full Text] [Related]
49. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient.
Knutson KL; Disis ML
Hum Immunol; 2002 Jul; 63(7):547-57. PubMed ID: 12072190
[TBL] [Abstract][Full Text] [Related]
50. Clonotype-specific avidity influences the dynamics and hierarchy of virus-specific regulatory and effector CD4(+) T-cell responses.
Liu J; Cao S; Peppers G; Kim SH; Graham BS
Eur J Immunol; 2014 Apr; 44(4):1058-68. PubMed ID: 24510524
[TBL] [Abstract][Full Text] [Related]
51. T-cell receptor transfer for boosting HIV-1-specific T-cell immunity in HIV-1-infected patients.
Mummert C; Hofmann C; Hückelhoven AG; Bergmann S; Mueller-Schmucker SM; Harrer EG; Dörrie J; Schaft N; Harrer T
AIDS; 2016 Sep; 30(14):2149-58. PubMed ID: 27258398
[TBL] [Abstract][Full Text] [Related]
52. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions.
Cohen CJ; Denkberg G; Lev A; Epel M; Reiter Y
J Mol Recognit; 2003; 16(5):324-32. PubMed ID: 14523945
[TBL] [Abstract][Full Text] [Related]
53. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
[TBL] [Abstract][Full Text] [Related]
54. Predicting CD4 T-cell epitopes based on antigen cleavage, MHCII presentation, and TCR recognition.
Schneidman-Duhovny D; Khuri N; Dong GQ; Winter MB; Shifrut E; Friedman N; Craik CS; Pratt KP; Paz P; Aswad F; Sali A
PLoS One; 2018; 13(11):e0206654. PubMed ID: 30399156
[TBL] [Abstract][Full Text] [Related]
55. Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.
Coosemans A; Vanderstraeten A; Tuyaerts S; Verschuere T; Moerman P; Berneman ZN; Vergote I; Amant F; VAN Gool SW
Anticancer Res; 2013 Dec; 33(12):5495-500. PubMed ID: 24324087
[TBL] [Abstract][Full Text] [Related]
56. Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy.
Ochi T; Nakatsugawa M; Chamoto K; Tanaka S; Yamashita Y; Guo T; Fujiwara H; Yasukawa M; Butler MO; Hirano N
Cancer Immunol Res; 2015 Sep; 3(9):1070-81. PubMed ID: 25943533
[TBL] [Abstract][Full Text] [Related]
57. Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity.
Schirmer D; Grünewald TG; Klar R; Schmidt O; Wohlleber D; Rubío RA; Uckert W; Thiel U; Bohne F; Busch DH; Krackhardt AM; Burdach S; Richter GH
Oncoimmunology; 2016 Jun; 5(6):e1175795. PubMed ID: 27471654
[TBL] [Abstract][Full Text] [Related]
58. T-Cell Receptor (TCR) Clonotype-Specific Differences in Inhibitory Activity of HIV-1 Cytotoxic T-Cell Clones Is Not Mediated by TCR Alone.
Flerin NC; Chen H; Glover TD; Lamothe PA; Zheng JH; Fang JW; Ndhlovu ZM; Newell EW; Davis MM; Walker BD; Goldstein H
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077649
[TBL] [Abstract][Full Text] [Related]
59. Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies.
Jahn L; van der Steen DM; Hagedoorn RS; Hombrink P; Kester MG; Schoonakker MP; de Ridder D; van Veelen PA; Falkenburg JH; Heemskerk MH
Oncotarget; 2016 Nov; 7(47):77021-77037. PubMed ID: 27776339
[TBL] [Abstract][Full Text] [Related]
60. Identification of T cell epitopes by the use of rapidly generated mRNA fragments.
Britten CM; Meyer RG; Graf C; Huber C; Wölfel T
J Immunol Methods; 2005 Apr; 299(1-2):165-75. PubMed ID: 15914199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
